Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2008/138577MEANS FOR TREATING INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES AND CANCER
WO 20.11.2008
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
Appl.No PCT/EP2008/003787 Applicant FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. Inventor HORN, Friedemann
This invention relates to a compound, wherein said compound is (a) a polynucleotide comprising or consisting of a base sequence of contiguous bases from the sequence of any one of SEQ ID NOs: 1 to 5, said base sequence being at least 15 bases in length; (b) a polynucleotide having at least 80% sequence identity to the polynucleotide of (a) over the entire length of said base sequence; (c) an analog or derivative of (a) or (b); or (d) a polynucleotide or analog or derivative thereof which is complementary to the full length of any one of (a) to (c); wherein said polynucleotide having at least 80% sequence identity, said analog, or said derivative is capable of interacting with a nucleic acid comprising a double-stranded part, said part comprising the sequence of any one of SEQ ID NOs: 1 to 5. The sequences of SEQ ID NOs: 1 to 5 define the Stat3-binding region of the gene encoding the micro RNA miR-21 and homologues thereof.
2.1990414Means for treating inflammatory diseases, autoimmune diseases and cancer
EP 12.11.2008
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No 07009444 Applicant FRAUNHOFER GES FORSCHUNG Inventor HORN FRIEDEMANN
This invention relates to a compound, wherein said compound is (a) a polynucleotide comprising or consisting of a base sequence of contiguous bases from the sequence of any one of SEQ ID NOs: 1 to 5, said base sequence being at least 15 bases in length; (b) a polynucleotide having at least 80% sequence identity to the polynucleotide of (a) over the entire length of said base sequence; (c) an analog or derivative of (a) or (b); or (d) a polynucleotide or analog or derivative thereof which is complementary to the full length of any one of (a) to (c); wherein said polynucleotide having at least 80% sequence identity, said analog, or said derivative is capable of interacting with a nucleic acid comprising a double-stranded part, said part comprising the sequence of any one of SEQ ID NOs: 1 to 5. The sequences of SEQ ID NOs: 1 to 5 define the Stat3-binding region of the gene encoding the micro RNA miR-21 and homologues thereof.
3.2008001711METHOD FOR PRODUCTION OF 1,5-DIDEOXY-1,5-IMINO HEXITOL FROM OXIME OR IMINE
JP 10.01.2008
Int.Class C07D 211/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
211Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
04with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
06having no double bonds between ring members or between ring members and non-ring members
36with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
40Oxygen atoms
44attached in position 4
46having a hydrogen atom as the second substituent in position 4
Appl.No 2007200331 Applicant UNIV MICHIGAN STATE Inventor HOLLINGSWORTH RAWLE I

PROBLEM TO BE SOLVED: To provide a method for preparation of 1,5-dideoxy-1,5-imino hexitols of hexose sugars from new hydroxy group-protected oxime intermediates.

SOLUTION: The method includes the processes of (a) reacting an acid ester or a hydrazide of a 5-hexulosonic acid oxime or alkylimine with hydrogen and a hydrogenation catalyst in an acidic solvent to form a 5-imino-5-deoxyaldonic acid lactam and (b) reducing the lactam with a reducing agent to form the 1,5-dideoxy-1,5-imino hexitol. The hexitols are useful as drugs.

COPYRIGHT: (C)2008,JPO&INPIT

4.2008303209SUGAR ALCOHOL ESTER OR ETHER, CHOLESTERIC LIQUID CRYSTAL ADDITIVE, LIQUID CRYSTAL COMPOSITION AND DISPLAY ELEMENT
JP 18.12.2008
Int.Class C07C 245/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
245Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
02Azo compounds, i.e. compounds having the free valencies of -N=N- groups attached to different atoms, e.g. diazohydroxides
06with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
08with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
Appl.No 2008086903 Applicant NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL & TECHNOLOGY Inventor AKIYAMA AKIHISA

PROBLEM TO BE SOLVED: To provide a new additive to be added to a cholesteric liquid crystal and to obtain a liquid crystal display element produced by the addition of the additive.

SOLUTION: The new sugar alcohol ester or ether is represented by general formula (1) [wherein R is a group represented by general formula (2) (wherein A is an aliphatic group; B and C are each a group selected from an ester, an ether and a methylene group or A-B- is a group selected from a hydrogen group or a methyl group; D is a bifunctional saturated hydrocarbon group; E is a group selected from a carbonyl group, a methylene group and an oxycarbonyl ethylene carbonyl group; and n is an integer of 1-6)]. The liquid crystal composition and the display element each comprises the same.

COPYRIGHT: (C)2009,JPO&INPIT

5.20080233604Methods For Identifying Compounds Capable of Modulating the Hydrolase Activity of Clca Protein
US 25.09.2008
Int.Class C12Q 1/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
34involving hydrolase
Appl.No 10590691 Applicant LEPISTO MATTI Inventor Lepisto Matti

Methods for identifying compounds capable of modulating the hydrolase activity of a CLCA protein include screening and computer modelling methods. The compounds, including antibodies, may be useful as therapeutic agents to treat a variety of diseases.

6.WO/2008/037036OLIGONUCLEOTIDE ARRAYS
WO 03.04.2008
Int.Class C07H 19/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
06Pyrimidine radicals
Appl.No PCT/BE2007/000111 Applicant KATHOLIEKE UNIVERSITEIT LEUVEN Inventor HERDEWIJN, Piet
The present invention provides for oligonucleotide arrays wherein the oligonucleotides comprise six- membered sugar-ring nucleosides, especially tetrahydropyran nucleosides, more specifically altritol nucleosides. The present invention also provides for the use of said oligonucleotide arrays for detecting target molecules in samples (diagnostic or experimental use). The present invention also provides for a method of detecting target molecules in samples by using said oligonucleotide arrays comprising six-membered sugar-ring nucleosides.
7.1999134PROCESS FOR THE PRODUCTION OF ANHYDROSUGAR ALCOHOLS
EP 10.12.2008
Int.Class C07D 493/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
493Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
02in which the condensed system contains two hetero rings
06Peri-condensed systems
Appl.No 07752855 Applicant ARCHER DANIELS MIDLAND CO Inventor SANBORN ALEXANDRA J
A process is provided for the preparation of anhydrosugar alcohols. The process involves heating a sugar alcohol or a monoanhydrosugar alcohol starting material in the presence of an acid catalyst and under pressure. Optionally the resulting product is purified. Very high purities are achieved, without necessitating the use of organic solvents in the process.
8.WO2008010318生分解性樹脂組成物
JP 24.01.2008
Int.Class C08L 67/04
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
67Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
04Polyesters derived from hydroxy carboxylic acids, e.g. lactones
Appl.No 2008525787 Applicant ユニチカ株式会社 Inventor 川原 光博
9.20080167326Method For Assessing the Predisposition and/or Susceptibility to Copd by Analysing Fgf-Bp1
US 10.07.2008
Int.Class A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
Appl.No 11910092 Applicant ASTRAZENECA AB Inventor Koopmann Witte

The present invention relates to the discovery of an association between the gene encoding FGF-BP1 (fibroblast growth factor-binding protein) and chronic obstructive pulmonary disease (COPD). The invention identifies a role for FGF-BP1 in COPD. The present invention therefore relates to diagnostic techniques for the detection of COPD by detecting all or part of this gene, its precursors or products (mRNA, cDNA, genomic DNA, or protein). The present invention also provides methods and as-says for identifying compounds which modulate FGF-BP1 and which may be used for treating respiratory diseases such as COPD. Furthermore, the invention relates to polymorphisms in the genes encoding FGF-BP1. The invention also relates to the use of polymorphisms in the FGF-BP1-encoding genes in assessing predisposition and/or susceptibility of an individual to chronic obstructive pulmonary disease (COPD).

10.WO/2008/131364METHODS OF DIAGNOSING ALZHEIMER'S DISEASE AND ASSOCIATED MARKERS
WO 30.10.2008
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No PCT/US2008/061068 Applicant TRANSLATIONAL GENOMICS RESEARCH INSTITUTE Inventor STEPHAN, Dietrich, A.
The present disclosure relates to genetic markers and methods of diagnosing and screening for late-onset Alzheimer's disease (LOAD). As such, the disclosure encompasses a whole-genome association analysis of single nucleotide polymorphisms (SNPs) of which a number are located within the GRB2-associated binding protein 2 (GAB2) gene as well as other markers associated with other genes. The disclosure identifies two novel haplotypes within the GAB2 gene, i.e., a LOAD risk-enhancing and a LOAD risk-decreasing haplotype. These haplotypes modify LOAD risk differentially in combination with APOE alleles. Further encompassed are therapeutic methods and agents of decreasing the deterioration of cells associated with LOAD.